| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 7.07▲ | 7.11▼ | 7.12▼ | 7.49▼ | 7.58▼ |
| MA10 | 7.07▲ | 7.16▼ | 7.26▼ | 7.59▼ | 7.35▼ |
| MA20 | 7.11▼ | 7.28▼ | 7.25▼ | 7.69▼ | 7.57▼ |
| MA50 | 7.25▼ | 7.43▼ | 7.60▼ | 7.53▼ | 7.64▼ |
| MA100 | 7.25▼ | 7.60▼ | 7.61▼ | 7.65▼ | 9.61▼ |
| MA200 | 7.45▼ | 7.65▼ | 7.55▼ | 7.68▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.005▲ | -0.017▼ | -0.015▼ | -0.061▼ | 0.001▲ |
| RSI | 33.498▼ | 34.632▼ | 36.787▼ | 42.657▼ | 44.644▼ |
| STOCH | 29.540 | 4.138▼ | 5.316▼ | 48.507 | 41.521 |
| WILL %R | -70.000 | -92.941▼ | -92.941▼ | -95.305▼ | -80.664▼ |
| CCI | -32.850 | -98.146 | -129.507▼ | -155.730▼ | -78.029 |
| ▼ MACD | $GYRE MACD(12,26,9) Crossed Below Zero | Set Alert |
|
Thursday, May 07, 2026 04:10 AM
Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to ...
|
|
Thursday, May 07, 2026 03:19 AM
In April 2026, Gyre initiated its adaptive Phase 2/3 clinical trial in oncology-related pulmonary complications, with the first patient enrolled. The trial is evaluating pirfenidone for ...
|
|
Tuesday, May 05, 2026 09:27 PM
Detailed price information for Gyre Therapeutics Inc (GYRE-Q) from The Globe and Mail including charting and trades.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 11/05/26 | 7.365 | 7.41 | 7.045 | 7.075 | 45,763 |
| 08/05/26 | 7.21 | 7.47 | 7.20 | 7.47 | 52,780 |
| 07/05/26 | 7.90 | 7.90 | 7.025 | 7.07 | 167,484 |
| 06/05/26 | 7.88 | 8.09 | 7.73 | 8.04 | 131,565 |
| 05/05/26 | 8.02 | 8.05 | 7.68 | 7.78 | 60,693 |
| 04/05/26 | 7.78 | 8.05 | 7.7251 | 7.92 | 74,016 |
| 01/05/26 | 7.68 | 7.89 | 7.45 | 7.80 | 70,899 |
| 30/04/26 | 7.41 | 7.70 | 7.41 | 7.68 | 43,952 |
| 29/04/26 | 7.70 | 7.70 | 7.30 | 7.35 | 47,255 |
| 28/04/26 | 7.63 | 7.76 | 7.63 | 7.67 | 44,339 |
|
|
||||
|
|
||||
|
|